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Abstract
Background: Diabetes-associated cognition decline is one of central nervous system complications in diabetic
mellitus, while its pathogenic mechanism remains unclear. In this study, 1H nuclear magnetic resonance-based
metabonomics and immunohistochemistry was used to explore key metabolic alterations in hippocampus of type 2
diabetic db/db mice with cognition decline in order to advance understanding of mechanisms underlying the
pathogenesis of the disease.
Results: Metabonomics reveals that lactate level was significantly increased in hippocampus of db/db mice with
cognition decline compared with age-matched wild-type mice. Several tricarboxylic acid cycle intermediates
including succinate and citrate were reduced in hippocampus of db/db mice with cognition decline. Moreover, an
increase in glutamine level and a decrease in glutamate and γ-aminobutyric acid levels were observed in db/db
mice. Results from immunohistochemistry analysis show that glutamine synthetase was increased and glutaminase
and glutamate decarboxylase were decreased in db/db mice.
Conclusions: Our results suggest that the development of diabetes-associated cognition decline in db/db mice is
most likely implicated in a reduction in energy metabolism and a disturbance of glutamate-glutamine shuttling
between neurons and astrocytes in hippocampus.
Keywords: Diabetes-associated cognition decline, Nuclear magnetic resonance, Metabonomics, Glutamate-
glutamine cycle
Background
Type 2 diabetes is a chronic and metabolic disease charac-
terized by hyperglycemia due to insulin resistance and β-
cell dysfunction [1, 2]. Its resultant complications are be-
coming main public health problems. Diabetes-associated
cognitive decline (DACD) as a central nervous systems
complication in type 2 diabetes has already been attracted
considerable attention, not only for its negative effect on
the brain but also its association with other neurodegener-
ative diseases [3–5]. DACD has been recognized in
diabetic patients [6] and animal models [1, 4, 7]. Hence, it
is of great interest and importance to explore the under-
lying mechanisms and develop treatment strategies for the
disease.
Metabolic and vascular disturbances have been found
to be implicated in the pathophysiology of cognitive im-
pairment in diabetes [3]. Hyperglycemia can affect
morphology of the neuron in the hippocampus and in
turn impair learning and memory [8, 9]. Artola et al.
found that the inhibition of long-term potentiation and
facilitation of long-term depression in the hippocampus
may contribute to learning and memory deficits associ-
ated with diabetes. Moreover, hippocampal neurons have
been shown to undergo apoptotic cell death under
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hyperglycemic conditions [10], while expression of the
astrocyte-specific glial fibrillary acidic protein (GFAP) is
enhanced [11]. Also alterations in dendritic spine length
and density were reported in diabetic animal models
[12]. So far, many factors have been found to influence
the development of DACD, such as brain vasculature,
glucose toxicity, oxidative stress, hypoglycemic episodes,
and glucose metabolism dysregulation. However, meta-
bolic alterations associated with the disease need to be
further explored.
Nuclear magnetic resonance (NMR)-based metabo-
nomic analysis as a systems biology approach aims to de-
tect the global metabolic information in biological
samples [13, 14]. It has been extensively applied in the
diagnosis and evaluation of diabetes and the provision of
crucial insights into the pathogenesis of diabetes [15, 16].
By using ex vivo 13C NMR approach with glucose and
acetate as substrate, we found enhanced pyruvate recyc-
ling pathway in earlier stage of type 1 diabetic rats induced
by streptozotocin, and disordered metabolic trafficking be-
tween the astrocyte and neuron in later stage, which may
be a regulated mechanism against metabolic impairments
[17]. In addition, we also found hypoglycemia induced by
insulin can affect different metabolic pathways, such as
neurotransmitter transition, energy metabolism, and other
metabolic equilibrium in a brain region-dependent man-
ner [18]. These results contribute to the understanding of
the underlying mechanisms that leads to brain damages in
type 1 diabetes. However, the global metabolic changes in
brain tissue of type 2 diabetes are not well understood.
To comprehensively profile the metabolic changes asso-
ciated with the development of DACD, type 2 diabetes
db/db mice were used and developed features of cognitive
decline with age. NMR-based metabonomics with key
protein analysis was performed to study the characteristics
of metabolism in the hippocampal samples obtained from
db/db mice with DACD. Therefore, the aims of the
present study were: (1) to investigate behavioral changes
in db/db mice with DACD, and (2) to explore metabolic
variations in hippocampus using NMR-based metabo-
nomics. The results will advance understanding of poten-
tial mechanisms underlying DACD.
Results
Learning and memory performance
The Morris water maze (MWM) test showed that escape
latency of db/db mice was significantly longer than that
of age-matched wild type (WT, Fig. 1a and b) mice. In
addition, db/db mice had a significantly shorter swim-
ming time and crossing number as compared with the
age-matched WT mice in the target quadrant during the
probe trial in the MWM test (Fig. 1c and d). Thus, re-
sults of the test indicate learning and memory deficits in
db/db mice at 17-wk of age.
Histopathological examination in hippocampus tissues
Figure 2 illustrates the histological changes in hippocam-
pus based on TUNEL assay and GFAP immunohisto-
chemistry. It can be seen that number of TUNEL-
positive cells were significantly increased in hippo-
campus of db/db mice with DACD compared to WT
mice (Fig. 2a-c, P < 0.01), which suggests that there
was more neuronal apoptosis in hippocampus of db/
db mice. Moreover, relative to WT mice, the expres-
sion of GFAP, which is a key indicator of astrocyte
Fig. 1 Performance of Morris water maze test in db/db (n = 7) and WT mice (n = 7). a Swim track; (b) Escape latency; (c) Time spent in goal area;
(d) Number of crossing the original platform. Significant level: *P < 0.05, **P < 0.01, ***P < 0.001
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reactivity, was increased significantly in db/db mice
with DACD (Fig. 2d–f, P < 0.01).
Metabonomic analysis of the hippocampus extracts
Representative 1H NMR-based metabolic profiling of the
hippocampus extracts obtained from 17-wk db/db and
WT mice was shown in Fig. 3. The spectral resonances
of the metabolites assigned based on previous studies
[19–21] and the 600 MHz library of the Chenomx NMR
suite 7.0 (Chenomx Inc., Edmonton, Canada) were shown
in Fig. 3b and Additional file 1: Table S1. Furthermore,
projection to latent structure discriminant analysis (PLS-
DA) was implemented to investigate the metabolic differ-
ence between db/db and WT mice (Fig. 4). As shown in
Fig. 4a, clear discrimination was observed between them
(R2X = 0.533, R2Y = 0.841, Q2Y = 0.585), which was vali-
dated by the permutation test (Fig. 4b). Figure 4c shows
the corresponding loading plot with color-coded correl-
ation coefficients (|r|) of PLS-DA, indicating metabolites
that contributed to the separation between two groups.
Fig. 2 Pathological changes in hippocampus of db/db and WT mice. Apoptosis was examined by the TUNEL assay ((a), WT mice; (b), db/db mice
with cognitive decline). Astrogliosis was evaluated by the GFAP method ((d), WT mice; (e), db/db mice). The numbers of TUNEL and GFAP-positive
cells were counted blindly, as shown in (c and F), and an average was taken from five different fields of hippocampus in each group of mice
(n = 4, Scale bars = 100 μm.). Significant level: **P < 0.01
Fig. 3 Representative 600 MHz 1H NMR spectra of hippocampus extracts from WT mice (a, n = 11) and db/db mice (b, n = 7)
Zheng et al. Molecular Brain  (2016) 9:40 Page 3 of 9
The results showed increased levels of lactate, glutamine
and taurine, and decreased levels of glutamate, N-acetyl
aspartate (NAA), citrate, glycine, choline, aspartate and
succinate in hippocampus of db/db mice with DACD as
compared with WT mice.
To further confirm the metabolic changes, the levels
of the metabolites were quantified and analyzed by t-test
as shown in Fig. 5 and Additional file 1: Table S1. NAA
level, a marker for neuronal viability, was decreased sig-
nificantly in db/db mice with DACD (9.79 ± 0.37 vs
10.46 ± 0.22, p < 0.001). Lactate content in hippocampus
of db/db mice with DACD was significantly increased
(27.36 ± 2.89 vs 19.97 ± 0.60, p < 0.001). In addition, sev-
eral tricarboxylic acid (TCA)-cycle-related metabolites,
such as pyruvate, succinate and citrate, were also found
significantly reduced in db/db mice with DACD. Taurine
is a sulfur-containing amino acid that plays important
roles on regulating osmolality of the astrocytes. In the
present study, a significantly elevated level of taurine
was observed in db/db mice with DACD (18.20 ± 0.83 vs
16.84 ± 0.45, p < 0.001).
Moreover, glutamate as an excitatory neurotransmitter
(18.18 ± 0.68 vs 20.81 ± 0.63, p < 0.001) and GABA as an
inhibitory neurotransmitter (5.59 ± 0.20 vs 6.11 ± 0.32, p <
0.001) were significantly reduced in hippocampus of db/
db mice with DACD relative to WT mice. In contrast, as
precursor and storage form of glutamate, the level of
glutamine was elevated significantly (12.98 ± 0.89 vs 11.48
± 0.57, p < 0.001). Thus, our data indicated the disturbance
of the glutamate-glutamine cycle homeostasis in db/db
mice with DACD.
Key enzymes determination in glutamate-glutamine cycle
To further explore the reasons that glutamate-glutamine
cycle influenced in db/db mice with DACD, we used im-
munohistochemistry and immunofluorescence to deter-
mine the alterations in some key enzymes involved in
this cycle, such as glutamine synthetase (GS), glutamin-
ase (GLS) and glutamate decarboxylase (GAD). GS, an
ubiquitous enzyme present in the astroglial cytoplasm
and involved in formation of glutamine from glutamate
[22], was shown to be raised in hippocampus of db/db
mice with DACD, which indicates an enhanced reaction
from glutamate to glutamine (Fig. 6). Our data also show
that immnuohistochemical labeling of GAD neurons
[23] with a monoclonal GAD67 antibody revealed a de-
creased density of stained neurons, indicating that the
pathway from glutamate to GABA was inhibited. In
addition, a similar result was also shown in labeling with
the anti-GLS antibody [24], which was consistent with
the reduced trend from glutamine into glutamate. Figure 7
illustrates the metabolic changes in hippocampus of db/db
mice with DACD relative to WT mice.
Fig. 4 PLS-DA score plot (a) and validation plot (b) based on the 1H NMR spectra of hippocampus samples obtained from db/db mice (red circle,
n = 7) and WT mice (■, n = 11). The coefficient-coded loading plot (c) corresponding to PLS-DA revealing the metabolites with large intensities
responsible for the discrimination of the corresponding score plot
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Discussion
The present study was conducted to investigate the be-
havioral and metabolic changes in db/db mice with
DACD. In the MWM test, we found that db/db mice
had significantly longer latency to locate the hidden plat-
form than WT mice. Moreover, number of crossing the
original platform site was significantly reduced in db/db
mice. The MWM test indicates cognitive ability was
impaired in 17-week-old db/db mice. To explore potential
mechanisms underlying DACD, we examined the change
of cellular and metabolic levels by immunohistochemistry
analysis and NMR-based metabonomics, respectively.
TUNEL is commonly applied to detect DNA fragmenta-
tion from apoptotic signaling cascades [25]. TUNEL assay
in the present study shows an increase in apoptotic cells
in hippocampus of db/db mice with DACD. Li et al. also
Fig. 6 Immunohistochemistry of glutamic acid decarboxylase (GAD), glutaminase (GLS) and glutamine synthetase (GS) in the hippocampus of WT
mice and db/db mice with cognitive decline
Fig. 5 Changes in metabolite levels in the hippocampus of db/db mice with cognitive decline (red circle, n = 7) and WT mice (■, n = 11) obtained
from NMR-based metabonomics. Significant level: *P < 0.05, **p < 0.01
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found hippocampal neuronal apoptosis in rats with type 1
diabetes associated cognitive impairment [26]. In addition,
GFAP is widely used as a specific marker of astrocytes
[27]. In the present study, an increase in number of
GFAP-positive cells in hippocampus of db/db mice with
DACD compared with WT mice may suggest that astro-
cytes were proliferated in db/db mice with DACD, which
is in good agreement with the previous work where they
found that diabetes-induced memory impairment was ac-
companied by astrogliosis [28]. Therefore, neuronal apop-
tosis and astrocytes proliferation may be responsible for
DACD in db/db mice.
Metabonomics reveals that DACD may be associ-
ated with energy metabolism disturbance. Since glu-
cose is the main source of energy in the mammalian
brain, regulation of glucose metabolism is critical for
maintaining normal brain physiology [29]. Glucose
metabolism is a catabolic process that firstly converts
glucose to pyruvate, and then pyruvate is oxidized to
CO2 and H2O under aerobic condition through TCA
cycle or transformed into lactate by anaerobic glycoly-
sis pathway. In the present study, a significant in-
crease in lactate level may indicate that anaerobic
glucose metabolism was enhanced in hippocampus of
db/db mice with DACD, which was further confirmed by
a decrease in several TCA intermediates, succinate and
citrate. In addition, conversion of glucose to lactate can
also occur in the presence of oxygen, which is known as
the Warburg effect or aerobic glycolysis [30]. Thus, an in-
creased lactate level may also indicate that DACD induced
the Warburg effect in hippocampus of db/db mice.
Although glucose is the main brain energy substrate,
glutamate is an important intermediate, linking the neu-
rotransmitters metabolism and TCA cycle [31]. Glutam-
ate homeostasis involves a mutual relationship between
the neuron and neighboring astrocytes [32]. In the
present study, DACD lead to reduced level of GLS and
increased GS, which resulted in altered glutamate-
glutamine cycle homeostasis in hippocampus of DACD
mice. The glutamate-glutamine cycle is a major regulatory
Fig. 7 Summary of the metabolic changes in the hippocampus tissue of db/db mice with cognitive decline including glucose metabolism and
glutamate–glutamine cycle compared with WT mice. In hyperglycemia circumstance, glycolysis is elevated, while aerobic oxidation is inhibited.
As precursor for glutamate, reduction of TCA intermediates, combining with lower levels of glutaminase (GLS) and glutamate decarboxylase
(GAD) in neuron, all contributes to the decreased level of glutamate and GABA. The reduced glutamate level, which is consistent with
attenuation of postsynaptic glutamate receptors, i.e. N-methyl-D-aspartate (NMDA) subtype, and inhibition of synaptic long-term potentiation
(LTP), may contribute to the pathogenesis of diabetes-associated cognitive decline. Keys: glutamate transporter 1 (GLT-1), glutamate aspartate
transporter 1 (GLAST-1), sodium-coupled neutral amino acid transporters (SNATs), glucose transporter (Glut 1)
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mechanism for fine tuning glutamate, glutamine and
GABA levels in the organisms [33]. Lyoo et al. have found
prefrontal altered glutamate-glutamine cycle in low cogni-
tive performance patients with type 1 diabetes by using
magnetic resonance imaging (MRI) [6]. However, due to
overlapping of the chemical shift of glutamate, glutamine
and GABA at 1.5-Tesla imaging, these signals were as-
cribed into only elevated glutamate which is a primary
neurotransmitter. In the present study, using high-field-
strength (14.09 Tesla) and tissue extraction technology,
we can acquire more detailed information in chemical
structure from an NMR spectrum. Thus, we found an in-
crease in glutamine and a decrease in glutamate and
GABA in db/db mice with DACD, which was in agree-
ment with the findings from semi-quantitative immuno-
histochemistry about the key proteins alterations in
glutamate-glutamine cycle. For instance, GS was strength-
ened in hippocampus of db/db mice with DACD, while
both GLS and GAD were attenuated compared with WT
mice. Thus, our results indicate that functional change of
glutamatergic neuron in diabetes may be a possible reason
underlying diabetes-related neurological complications.
On the one hand, glutamate as an important neurotrans-
mitter is involved in glutamate-glutamine cycle in brain
[6]. On the other, glutamate is also known as a key mol-
ecule in the processes of learning and memory, which is
released from the pre-synaptic nerve terminal and inter-
acts with postsynaptic receptors, such as N-methyl-D-
aspartate (NMDA) [6]. It is now well documented that
the NMDA receptor expression is reduced in synaptic
densities from the brain of chronic streptozotocin-
induced type 1 diabetic rats [34] and other animal
models with T2D [35]. However, the detailed relation-
ship between DACD and the change in glutamate level
and NMDA receptor activity remains unclear and needs
further investigation.
Conslusion
In the present study, we found that cognitive ability in db/
db mice at 17-wk of age was impaired. To further explore
potential mechanisms underlying this phenomenon, we
investigated changes in cellular and metabolic levels using
immunohistochemistry and NMR-based metabonomics,
respectively. Results show that neuronal apoptosis and
astrocytes proliferation may be responsible for DACD in
db/db mice. In addition, metabonomics reveal that DACD
development in db/db mice may be implicated in a reduc-
tion in energy metabolism and a disturbance of glutamate-
glutamine cycle in hippocampus.
Methods
Animals
Male 15-wk db/db (BKS.Cg-m+/+ Leprdb/J, n = 11) and
WT (C57BLKS/J-m+/+db, n = 15) mice were purchased
from Mode Animal Research Center of Nanjing University.
The mice were kept in a specific pathogen free colony
of the Laboratory Animal Center of Wenzhou Medical
University (Wenzhou, China) with regulated temperature
and humidity and a 12:12-h light–dark cycle. The mice
were fed with tap water and standard mice chow ad la-
bium during the experiments. Body weight and fast blood
glucose level was monitored weekly. The study was con-
ducted in accordance to the “Guide for the Care and Use
of Laboratory Animals” and approved by the Institutional
Animal Care and Use Committee of Wenzhou Medical
University (Document: wydw2012-0083).
Morris water maze (MWM) test
The MWM test was performed according to a previ-
ously published method [36, 37], with a minor modi-
fication. Briefly, the test was conducted in a circular
pool (diameter = 110 cm, height = 30 cm), filled with
water made opaque with nontoxic paint and main-
tained at 26 ± 1 °C. The circular escape platform
(diameter = 7 cm) was submerged 1 cm below the
water surface. Cues were hung at four locations at
the north, west, south, and east corners of the swim-
ming pool wall, respectively. Four consecutive train-
ing days were performed, and on each-training day
the mice swam four trials (rotating initial placement
each time) for 60 s or until they located and climbed
onto the hidden escape platform (within 60 s). The
mice that failed to find the platform within 60 s
were guided to be there by the operator. In addition,
the mice were tested in a single 90 s probe trial
without the platform at the last training day. The
swimming path length, escape latency, and the swim-
ming velocity were recorded by a computer system.
Samples collection and 1H NMR spectra acquisition
The mice were sacrificed by decapitation at 17-wk of
age, and specimens of hippocampus were dissected
immediately, snap-frozen in liquid nitrogen and stored
at −80 °C until use. Then the preparation of hippo-
campus extracts and acquisition of 1H-NMR spectra
were performed using our previous method [17, 20, 21].
For NMR analysis, the hippocampus extracts were re-
suspended in 500 μL of D2O and centrifuged, and
then the supernatant was transferred to a 5 mm
NMR tube. 1H NMR spectra were acquired on a Bru-
ker AVANCE III 600 MHz NMR spectrometer with a
5-mm TXI probe (Bruker BioSpin, Rheinstetten,
Germany) at 25 °C. One-dimensional ZGPR pulse se-
quence was used, and the main parameters were set
as follows: data points, 64 K; spectral width, 12,000 Hz; re-
laxation delay, 10 s.
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Multivariate pattern recognition analysis
The 1H NMR spectrum was phase- and baseline-
corrected and integrated to binning data with a size of
0.01 ppm from 0.4 to 10.0 ppm using the Bruker Topspin
2.1 software package. For NMR spectra recorded in hippo-
campal extracts, the region of about δ 4.69–5.04 was re-
moved to eliminate artifacts related to the residual water
resonance. The remaining spectral segments were normal-
ized to the total sum of the spectral intensity to compen-
sate for variations in total sample volume. The normalized
integral values were then subjected to multivariate pattern
recognition analysis using the SIMCA-P+ V12.0 software
package (Umetrics, Umea, Sweden). Data were visualized
by the scores plots of the first two principal components
to provide the 2D information [38].
The projection to latent structure discriminant ana-
lysis (PLS-DA), which is a supervised method, was car-
ried out for class discrimination and biomarker
identification. Data were visualized by plotting the scores
of the first two principal components (PC1 and PC2) to
provide the most efficient 2D representation of the in-
formation, where the position of each point along a
given axis in the scores plot was influenced by variables
in the same axis in the loading plot. PLS-DA revealed
differences in the extracts composition of different
groups, which were necessary to eliminate outliers and
enhance the quality of the PCA model. The loading
plots, which were assessed by the absolute value of the
correlation coefficient, |r|, can identify the metabolites
contribute to the separation of metabolic profiles [39]. A
100 random permutation test was performed to evaluate
the robustness of the PLS-DA model. Meanwhile, two
parameters were calculated: R2, the explained variance
in the matrix, and Q2, the predictive capability of the
model, which are commonly used to indicate the quality
of model [40].
Histology assay
Brain tissues were collected, fixed in PBS-buffered
10 % formalin for at least 24 h, and embedded in
paraffin. The samples were then sectioned using a
slicing machine (Leica, Germany) and mounted in
Poly-L-Lysine-coated slides for histopathological examin-
ation. DNA fragmentation in vivo was detected by the one
step TUNEL Apoptosis Assay KIT (Roche, Mannheim,
Germany) and the images were captured with a Nikon
ECLPSE 80i (Nikon, Japan).
For immunohistochemistry or immunofluorescence ex-
periments, slides were placed in 1:20 citrate buffer in a
decloaking chamber under pressure for 5 min after depar-
affinizing, dehydrating and washing, depressurized for
5 min, and allowed to cool. Endogenous peroxidase was
quenched using 15-min incubation in distilled water con-
taining 0.3 % hydrogen peroxide. The transverse paraffin
sections were incubated in 3 % H2O2 and 80 % carbinol
for 30 min and then in blocking solution at room
temperature for 1 h. Subsequently, the sections were incu-
bated with the following primary antibodies overnight at
4 °C, including GFAP (1:1000, Abcam), GS (1:200, Santa
Cruz), GAD65 (1:500, Abcam), and GLS (1:100, Abcam).
After triple washing in PBS, the sections were incubated
with horseradish peroxidase-conjugated secondary anti-
bodies at 37 °C for 1 h. For immunohistochemistry, the re-
action was stopped with 3,3’-diaminobenzidine and the
image were captured at a magnification of 200 fold. For
immunofluorescence staining, after primary antibody in-
cubation, the sections were washed and then incubated
for 1 h with secondary antibody (1:400) and the images
were captured on Nikon ECLIPSE Ti microscope. The
total number of TUNEL- and GFAP-positive neurons was
manually counted from the five selected sections of the
hippocampus.
Statistical analysis
Difference analysis in identified metabolites between the
DACD and WT mice was carried out by t-test using
SPSS software (version 13.0, SPSS). P value of < 0.05 was
considered statistically significant.
Statement on ethics approval
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The data have been deposited to the KiMoSys repository
(http://kimosys.org) [41] with the dataset identifier Data
EntryID 91.
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